SEC Form 4 · accession 0001127602-18-036606
HAEMONETICS CORP · HAE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ronald G Gelbman
Director
Period of report
Dec 14, 2018
Accepted (ET)
Dec 18, 2018 · 4:56 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000313143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Dec 14, 2018 | S | 4,329 | $103.02 | D | 53,062 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.96 to $103.10, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2This number includes unvested restricted stock units previously reported.